DECANBIO

Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer

 Coordinatore COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Dr.
Nome: Jérôme
Cognome: Garin
Email: send email
Telefono: +33 4 38 78 96 56
Fax: +33 4 38 78 50 51

 Nazionalità Coordinatore France [FR]
 Sito del progetto http://decanbio.eu
 Totale costo 3˙910˙866 €
 EC contributo 2˙907˙412 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-03-01   -   2012-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Dr.
Nome: Jérôme
Cognome: Garin
Email: send email
Telefono: +33 4 38 78 96 56
Fax: +33 4 38 78 50 51

FR (PARIS 15) coordinator 0.00
2    "BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"

 Organization address address: Soranou Efesiou 4
city: ATHENS
postcode: 11527

contact info
Titolo: Mr.
Nome: Dimitris
Cognome: Raptis
Email: send email
Telefono: +30 2 106597574
Fax: +30 2 106597571

EL (ATHENS) participant 0.00
3    ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

 Organization address address: 3 Avenue Victoria
city: PARIS
postcode: 75004

contact info
Titolo: Mr.
Nome: Michel
Cognome: Bilis
Email: send email
Telefono: 33149812001
Fax: 33149812199

FR (PARIS) participant 0.00
4    DIAGNOSWISS SA

 Organization address address: ZI LES ILETTES SECTEUR 4
city: MONTHEY
postcode: 1870

contact info
Titolo: Dr.
Nome: Frédéric
Cognome: Reymond
Email: send email
Telefono: 41244714900
Fax: 41244714901

CH (MONTHEY) participant 0.00
5    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH

 Organization address address: Raemistrasse 101
city: ZUERICH
postcode: 8092

contact info
Titolo: Dr.
Nome: Bruno
Cognome: Domon
Email: send email
Telefono: +41 4 46 33 20 88
Fax: +41 44 633 10 51

CH (ZUERICH) participant 0.00
6    ENTELECHON GMBH

 Organization address address: INDUSTRIESTRASSE 1
city: BAD ABBACH
postcode: 93077

contact info
Titolo: Dr.
Nome: Werner
Cognome: Deininger
Email: send email
Telefono: +49 9419468360
Fax: +49 9419468366

DE (BAD ABBACH) participant 0.00
7    FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III

 Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3
city: MADRID
postcode: 28029

contact info
Titolo: Mr.
Nome: Juan José
Cognome: Collazo Nieto
Email: send email
Telefono: +34 917 328 000
Fax: +34 912 246 980

ES (MADRID) participant 0.00
8    INSTITUT CURIE

 Organization address address: 26, rue d'Ulm
city: PARIS
postcode: 75248

contact info
Titolo: Prof.
Nome: Claude
Cognome: Huriet
Email: send email
Telefono: +33 1 44 32 40 53
Fax: +33 1 43255271

FR (PARIS) participant 0.00
9    Luxembourg Institute of Health

 Organization address address: Val Fleuri 84
city: LUXEMBOURG
postcode: 1526

contact info
Titolo: Mr.
Nome: Daniel
Cognome: Cardao
Email: send email
Telefono: +352 26 970 1
Fax: +352 26 970 719

LU (LUXEMBOURG) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

decanbio    tests    performed    grade    validation    throughput    protein    biomarker    quantification    biomarkers    elisa    cancer    strategy    time    spectrometry    mass    bladder    discovery    patients    clinical    mrm   

 Obiettivo del progetto (Objective)

'In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of “personalized medicine” approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers’ interest and investments, the rate of introduction of novel biomarkers in clinical practice is extremely disappointing. The main aim of DECanBio is to implement a strategy for protein biomarker discovery and validation relying on the use of “state of the art” mass spectrometry instrumentation for quantitative analysis of proteins. For the first time, the potential of MRM-Mass Spectrometry (MRM-MS) will be tested in the scope of a large scale validation protocol of cancer protein biomarkers. This analysis will be performed in parallel to the application of miniaturized high-throughput ELISA tests for protein quantification. DECanBio strategy will be applied to issues related to bladder cancer. Specifically, a restricted number of urinary protein biomarkers enabling the detection of recurrences during the monitoring period of patients treated for bladder tumour will be validated. The work will be performed in priority for the follow-up of low-grade superficial bladder tumours (Ta stage), which, after initial resection (without BCG therapy), are likely to evolve towards remission, recurrence, or progression to a high-grade tumor. The MRM and ELISA tests developed herein aim at the high-throughput quantification of these markers in urine. Collectively, the project has the ambition to settle a whole experimental pipe-line, from the search for new bladder cancer biomarker candidates, to their thorough evaluation and validation in clinical environment. We anticipate that the tools and knowledge that will be developed here will greatly facilitate translational studies for other diseases as well.'

Altri progetti dello stesso programma (FP7-HEALTH)

NANOMAL (2012)

Development of a handheld antimalarial drug resistance diagnostic device using nanowire technology

Read More  

MOMI (2011)

Missed Opportunities in Maternal and Infant Health: reducing maternal and newborn mortality and morbidity in the year after childbirth through combined facility- and community-based interventions

Read More  

CANCERALIA (2011)

Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tumours

Read More